Highlights from ADA 2023

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/71/0d/9f/710d9fb0-cc0e-a2e5-bb5d-e3172f7edad6/mza_17901817495047371423.jpg/600x600bb.jpg

Diabetes Knowledge into Practice Podcast

Liberum IME

23 episodes

3 days ago

A summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge into Practice (https://diabetes.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.

Medicine

Health & Fitness

RSS

All content for Diabetes Knowledge into Practice Podcast is the property of Liberum IME and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/1944169/1944169-1633442888085-826f56282e6e7.jpg

Highlights from ADA 2023

Diabetes Knowledge into Practice Podcast

19 minutes 45 seconds

2 years ago

Highlights from ADA 2023

Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 2023) congress. The congress featured over 200 scientific sessions and symposia, and 1,400 posters. Among the topics discussed are trials investigating therapies to treat obesity in patients with type 2 diabetes (T2D), as well as discussion about remission and what it really means for T2D.

For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠) or connect on ⁠LinkedIn⁠. Disclosures

Prof. Francisco Giorgino:

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Richard E. Pratley

Research grant: Dompe, Novo Nordisk

Honoraria for lectures, presentations and education events: Merck, Novo Nordisk

Consulting: Bayer AG, Endogenex Inc., Gasherbrum Bio Inc., Henguri (USA) Ltd. Intas Pharmaceuticals Inc. Eli Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., Sun Pharmaceutical Industries

Target Audience:

Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists

Geographic: Global (ex US and UK audiences)

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.